Oncocyte Pricing of $13.86 Million Public Offering of Common Stock
03 avr. 2023 08h00 HE
|
Oncocyte Corporation
IRVINE, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), (“Oncocyte” or the “Company”), a precision diagnostics company, announced today the entry into an agreement...
Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K
31 mars 2023 17h00 HE
|
Oncocyte Corporation
IRVINE, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced plans to file a Form 12b-25 with the U.S. Securities and...
Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call
29 mars 2023 16h01 HE
|
Oncocyte Corporation
IRVINE, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it has changed the date of its previously announced...
Oncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results
15 mars 2023 16h01 HE
|
Oncocyte Corporation
IRVINE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it will release its fourth quarter and full year 2022...
Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer
02 mars 2023 09h00 HE
|
Oncocyte Corporation
IRVINE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that Joshua Riggs has been appointed as its Chief Executive...
Oncocyte Completes Razor Genomics Transaction
22 févr. 2023 08h00 HE
|
Oncocyte Corporation
Company retains 30% stake while eliminating operating expense and future development obligations Represents next step in plan to focus product strategy IRVINE, Calif., Feb. 22, 2023 (GLOBE...
Oncocyte Announces Initiatives to Focus Corporate Strategy
16 déc. 2022 08h00 HE
|
Oncocyte Corporation
IRVINE, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a reduction in force involving over 40% of Oncocyte’s workforce...
Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors
30 nov. 2022 18h05 HE
|
Oncocyte Corporation
IRVINE, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte Announces Executive Leadership Changes
30 nov. 2022 18h00 HE
|
Oncocyte Corporation
IRVINE, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte Reports Third Quarter 2022 Financial Results
10 nov. 2022 16h30 HE
|
Oncocyte Corporation
IRVINE, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...